Cell Death and Disease Submission Guide
Cell Death & Disease's submission process, first-decision timing, and the editorial checks that matter before peer review begins.
Readiness scan
Before you submit to Cell Death & Disease, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Key numbers before you submit to Cell Death & Disease
Acceptance rate, editorial speed, and cost context — the metrics that shape whether and how you submit.
What acceptance rate actually means here
- Cell Death & Disease accepts roughly Selective Springer Nature open-access journal of submissions — but desk rejection runs higher.
- Scope misfit and framing problems drive most early rejections, not weak methodology.
- Papers that reach peer review face a different bar: novelty, rigor, and fit with the journal's editorial identity.
What to check before you upload
- Scope fit — does your paper address the exact problem this journal publishes on?
- Desk decisions are fast; scope problems surface within days.
- Cover letter framing — editors use it to judge fit before reading the manuscript.
How to approach Cell Death & Disease
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Scope fit |
2. Package | Prepare Springer Nature package |
3. Cover letter | Submit online |
4. Final check | Editorial assessment |
Quick answer: This Cell Death and Disease submission guide is for cell-death and disease researchers evaluating their work against the journal's mechanism and disease bar.
The journal is selective (~25-30% acceptance, 30-40% desk rejection). The editorial standard requires substantive cell-death mechanism contributions linked to disease.
Run a Cell Death And Disease pre-submission readiness check before clicking submit, or work through this guide manually.
If you're targeting Cell Death and Disease, the main risk is descriptive framing, weak disease-mechanism connection, or missing in-vivo validation.
From our manuscript review practice
Of submissions we've reviewed for Cell Death and Disease, the most consistent desk-rejection trigger is descriptive cell-death observations without rigorous disease-mechanism analysis.
How this page was reviewed
This page was researched from Cell Death and Disease's author guidelines, Springer Nature editorial-policy materials, Clarivate JCR data, SciRev community reports, and Manusights internal analysis of submissions to Cell Death and Disease and adjacent venues.
Source limitations: Springer Nature publishes the current guide to authors, editorial policies, open-access model, and submission workflow. It does not publish manuscript-level desk-screen notes. Manusights observations are anonymized pre-submission review patterns and are included only as practical author guidance.
After the official guidance, the practical screen is the set of failure patterns we see when the abstract, figures, disease model, functional validation, translational evidence, supplementary files, and cover letter do not connect cell death to disease.
For the underlying journal profile, see Cell Death and Disease.
What are Cell Death and Disease journal metrics?
Metric | Value |
|---|---|
Impact Factor (2024 JCR) | 9.6 |
5-Year JIF | ~9+ |
CiteScore | 14.0 |
Acceptance Rate | ~25-30% |
Desk Rejection Rate | ~30-40% |
First Decision | 4-8 weeks |
APC (Open Access) | $3,300 (2026) |
Publisher | Springer Nature |
Source: Clarivate JCR 2024, Springer Nature editorial disclosures (accessed April 2026).
What are Cell Death and Disease submission requirements and timeline?
Requirement | Details |
|---|---|
Submission portal | Springer Nature Editorial Manager |
Article types | Original Article, Review, Letter |
Article length | 8-15 pages |
Cover letter | Required |
First decision | 4-8 weeks |
Peer review duration | 8-14 weeks |
Source: Cell Death and Disease author guidelines.
What should the submission snapshot prove?
What to pressure-test | What should already be true before upload |
|---|---|
Disease-mechanism contribution | Manuscript links cell-death mechanism to specific disease |
Functional validation | Knockouts, knockdowns, or comparable functional evidence |
In-vivo or clinical validation | Animal models or patient samples appropriate to the disease |
Translational relevance | Connection to therapeutic application |
Cover letter | Establishes the disease-mechanism contribution |
What this page is for
Use this page when deciding:
- whether the disease-mechanism contribution is substantive
- whether functional validation is rigorous
- whether translational relevance is direct
What should already be in the package
- a clear disease-mechanism contribution
- rigorous functional validation
- in-vivo or clinical validation
- translational relevance
- a cover letter establishing the contribution
What package mistakes trigger early rejection?
- Descriptive cell-death observations without disease relevance.
- Weak functional or in-vivo validation.
- Missing translational connection.
- Basic cell biology without disease focus.
What makes Cell Death and Disease a distinct target
Cell Death and Disease is a flagship cell-death-in-disease journal.
Disease-focus standard: the journal differentiates from Cell Death and Differentiation (basic cell-death biology) by demanding disease relevance.
Functional and in-vivo expectation: editors expect functional and in-vivo or clinical evidence.
The 30-40% desk rejection rate: decisive editorial screen.
What should a strong cover letter sound like?
The strongest Cell Death and Disease editor-facing notes establish:
- the disease-mechanism contribution
- the functional validation
- the in-vivo or clinical evidence
- the translational relevance
How should authors diagnose pre-submission problems?
Problem | Fix |
|---|---|
Descriptive framing | Add functional studies and disease relevance |
In-vivo validation is missing | Add animal model or patient sample analysis |
Translational relevance is weak | Articulate therapeutic application |
How Cell Death and Disease compares against nearby alternatives
Method note: the comparison reflects published author guidelines and Manusights internal analysis. We have not personally been Cell Death and Disease authors; the boundary is publicly documented editorial behavior. Pros and cons are based on documented editorial scope.
Factor | Cell Death and Disease | Cell Death and Differentiation | Apoptosis | Cancer Cell Death |
|---|---|---|---|---|
Best fit (pros) | Cell death in disease with translational evidence | Basic cell-death biology | Apoptosis-focused research | Cancer-cell-death specific |
Think twice if (cons) | Topic is basic cell biology | Topic is disease-focused | Topic is non-apoptotic | Topic is non-cancer disease |
Submission portal
Cell Death and Disease submissions go through Springer Nature's online submission system, accessible from the journal's author hub. The submission system performs an initial quality check, then an Editor is assigned to decide whether to send the manuscript for external review.
Papers judged by the editors to be of insufficient general interest or scope are rejected promptly without external review. The journal accepts unsolicited Original Articles, Reviews, and Letters in cell death biology and disease.
Submission checklist
Cell Death and Disease requires these at first submission:
- main manuscript file with figures embedded for review
- cover letter establishing the disease-mechanism contribution
- author contribution statement (CRediT-style)
- data availability statement aligned with Springer Nature Data Policy Type 3
- ethics declarations (animal work, human subjects, consent)
- competing interests declaration
- suggested independent reviewers (authors are welcome to suggest)
- for revised submissions, a rebuttal letter with point-by-point response and a marked-up version highlighting changes
- for papers containing western blots or images from flow cytometry / confocal microscopy / IHC / ICC, original uncropped and unprocessed images
For Cell Death and Disease submissions, the most common artifact-related issue is missing or cropped original blot images. The journal's Data Policy Type 3 commitment means materials must be freely available to non-commercial researchers, and editors increasingly request the raw image set during initial screening rather than at revision.
Readiness check
Run the scan while Cell Death & Disease's requirements are in front of you.
See how this manuscript scores against Cell Death & Disease's requirements before you submit.
Editorial triage timeline
Cell Death and Disease manuscripts move through a four-stage editorial timeline. Knowing the realistic shape of this window prevents authors from misinterpreting silence as a negative signal.
Day 0 to 3: Editorial quality check
The submission system performs a formatting check. Editorial staff verify that the manuscript meets Springer Nature formatting requirements, that ethics and data statements are present, and that the cover letter establishes scope fit.
Day 3 to 14: Editor assignment and triage decision
An Editor is assigned and decides whether to send the manuscript for external peer review. Papers judged of insufficient general interest, weak disease-mechanism contribution, or scope mismatch are rejected without external review at this stage. The Editor-in-Chief contacts the author directly with desk-rejection decisions.
Week 3 to 6: External peer review
Manuscripts sent for review are evaluated by at least one independent reviewer, often two or more. Reviewers are given 14 days from acceptance to submit their reports. Reviewer turnaround is the largest source of timeline variance.
Week 6 to 10: Decision and revision
The handling editor synthesizes reviewer reports and returns a decision. Most decisions are major revision, minor revision, or rejection. Revised submissions require both a rebuttal letter and a marked-up manuscript highlighting changes.
Submit If
- the disease-mechanism contribution is substantive
- functional validation is rigorous
- in-vivo or clinical validation is included
- translational relevance is direct
Think Twice If
- the abstract names a disease phenotype but the figures mostly show cell-death markers without disease-relevant consequence
- the methods lack functional rescue, perturbation, in-vivo, or patient-sample evidence for the pathway claim
- the cover letter cannot explain why Cell Death and Disease is a better owner than Cell Death and Differentiation or a specialty venue
What to read next
- Is Cell Death and Disease a good journal?
Before upload, run your manuscript through a Cell Death and Disease mechanism readiness check.
This page handles the public submission rules; the draft still needs a journal-specific fit check. The review tells you whether your paper clears the Cell Death and Disease fit check before upload, especially around cell-death pathway story without a disease decision, functional evidence that proves a marker change but not disease relevance, and cover letter that cannot explain why this is not Cell Death and Differentiation. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.
Decision risks before submitting to Cell Death and Disease
Across cell-death-disease manuscripts targeting Cell Death and Disease, three failure modes account for many early rejections. They are visible in the abstract, figures, disease model, functional validation, translational framing, supplementary files, and cover letter before the submission reaches external reviewers.
Cell-death pathway story without a disease decision
Across Manusights submission reviews for cancer, neurodegeneration, cardiovascular, immune, metabolic, and inflammatory-disease manuscripts targeting Cell Death and Disease, the most common failure is not weak cell biology. It is unclear disease ownership. The abstract describes apoptosis, autophagy, necroptosis, ferroptosis, pyroptosis, or senescence; the figures show pathway markers; the methods use cultured cells or a disease model; but the cover letter does not explain what disease mechanism, therapeutic vulnerability, biomarker interpretation, or translational decision the work changes.
The stronger package makes the disease claim visible from page one. The abstract should name the disease context and the specific cell-death mechanism under test. The main figures should connect pathway manipulation to a disease-relevant phenotype, not only to marker shifts. The methods should explain why the model, patient material, organoid, animal system, or perturbation strategy is appropriate for the disease claim. The discussion should avoid broad therapeutic language unless the evidence supports it.
Cell Death and Disease is a better target when Cell Death and Differentiation would be too basic, Oncogene or Cancer Letters would be too cancer-specific, Molecular Therapy would overemphasize intervention, and Scientific Reports would understate the disease-mechanism contribution.
If your manuscript still reads like general cell-death biology, it may need a different journal or more disease evidence. A Cell Death and Disease mechanism readiness check can identify whether the abstract, figures, methods, and cover letter support the disease-mechanism claim.
Functional evidence that proves a marker change but not disease relevance
Many Cell Death and Disease submissions include functional assays, but the assays do not always support the manuscript's translational language. We see this when viability, apoptosis marker, ROS, mitochondrial, autophagy, or pathway-readout figures are interpreted as disease mechanism without showing that the same perturbation changes a disease-relevant phenotype. The cover letter may claim therapeutic implication, but the methods and supplementary files only prove that a pathway changes under artificial conditions.
The stronger evidence package asks what the disease reader needs to believe. If the paper claims therapeutic relevance, the figures should show dose, timing, rescue, comparator, or model evidence that connects the mechanism to disease behavior. If it claims biomarker relevance, the methods should show patient-sample logic, cohort interpretation, or disease-stage reasoning. If it claims mechanism, the manuscript should not rely only on inhibitor data without genetic or orthogonal confirmation. The cover letter should state exactly which manuscript component proves disease relevance.
This distinction matters because Cell Death and Disease sits between basic cell-death mechanism and translational disease biology. A paper can be technically competent and still be wrong for the journal if the disease connection is late, decorative, or overstated. Conversely, a focused manuscript with modest scope can be a strong fit if the figures and methods prove a clear disease-linked cell-death mechanism.
Cover letter that cannot explain why this is not Cell Death and Differentiation
The Cell Death family creates a specific routing problem. We often see Cell Death and Disease submissions whose cover letters describe a cell-death mechanism but do not explain why the disease-focused journal, rather than Cell Death and Differentiation, owns the paper. The reverse also happens: authors submit disease-adjacent work here when the evidence is actually a basic mechanism story. Editors can see this mismatch quickly because the title, abstract, figure order, and cover letter point to different audiences.
The stronger letter makes the route explicit. It should say why the disease context is central, which disease-relevant manuscript component carries the claim, and why adjacent venues such as Cell Death and Differentiation, Oncogene, Cancer Letters, Molecular Therapy, or Journal of Experimental Medicine are less precise. It should also avoid claiming clinical translation if the manuscript only has cultured-cell data. A disciplined cover letter can prevent a good manuscript from being read as basic cell biology wearing a disease label.
When the route is right, the whole package aligns: the abstract names a disease mechanism, the figures prove functional relevance, the methods support the model choice, the supplementary files carry confirmatory evidence, and the references show awareness of recent Cell Death and Disease work.
Check disease mechanism substance before submitting to Cell Death and Disease →
Frequently asked questions
Submit through Springer Nature Editorial Manager. The journal accepts unsolicited Original Articles, Reviews, and Letters on cell death in disease. The cover letter should establish the disease-mechanism contribution.
Cell Death and Disease's 2024 impact factor is around 9.6. Acceptance rate runs ~25-30% with desk-rejection around 30-40%. Median first decisions in 4-8 weeks.
Original research on cell death in disease: cancer cell death, neurodegeneration, cardiovascular cell death, immune-mediated cell death, and disease-related cell-death pathways. The journal expects mechanistic contributions linking cell death to disease.
Most reasons: descriptive cell-death observations without disease relevance, weak functional or in-vivo validation, missing translational connection, or scope mismatch (basic cell biology without disease focus).
Sources
Final step
Submitting to Cell Death & Disease?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Target journal carried over: Cell Death & Disease
Anthropic Privacy Partner. Zero-retention manuscript processing.